Novo Nordisk A/S (NVO) : Traders are bullish on Novo Nordisk A/S (NVO) as it has outperformed the S&P 500 by a wide margin of 0.41% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.17%, relative to the S&P 500. The stock has risen by 4.72% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.62% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.67% and the 50-Day Moving Average is 8.06%.The 200 Day SMA reached 12.62% Novo Nordisk A/S has dropped 9.26% during the last 3-month period . Year-to-Date the stock performance stands at -18.42%.
Company shares have received an average consensus rating of Hold for the current week Novo Nordisk A/S (NYSE:NVO): stock was range-bound between the intraday low of $46 and the intraday high of $46.55 after having opened at $46.54 on Fridays session. The stock finally closed in the red at $46.54, a loss of -0.26%. The stock remained in the red for the whole trading day. The total traded volume was 1,449,309 shares. The stock failed to cross $46.55 in Fridays trading. The stocks closing price on Thursday was $46.12.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.